TransThera Sciences (Nanjing) Inc
Company Profile
Business description
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its Core Product Tinengotinib is a unique multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
Contact
Biotech and Pharmaceutical Valley
3rd floor, Building 9, Accelerator Phase 2
Jiangbei New Area
Jiangsu Province
Nanjing210032
CHNT: +86 2558216200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
121
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors too optimistic about ASX growth story
stocks
Stellar growth from ASX retailer but markets still too optimistic
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,103.10 | 47.20 | -0.52% |
| CAC 40 | 7,777.85 | 24.43 | 0.32% |
| DAX 40 | 24,172.86 | 148.08 | 0.62% |
| Dow JONES (US) | 44,458.61 | 483.52 | 1.10% |
| FTSE 100 | 9,165.35 | 17.54 | 0.19% |
| HKSE | 25,592.33 | 622.65 | 2.49% |
| NASDAQ | 21,681.90 | 296.50 | 1.39% |
| Nikkei 225 | 43,274.67 | 556.50 | 1.30% |
| NZX 50 Index | 12,766.54 | 6.86 | 0.05% |
| S&P 500 | 6,445.76 | 72.31 | 1.13% |
| S&P/ASX 200 | 8,827.10 | 53.70 | -0.60% |
| SSE Composite Index | 3,683.46 | 17.55 | 0.48% |